Abstract
Chronic granulomatous disease is a genetic disorder responsible for a defect in the NADPH oxidase of phagocytic cells. It impairs the oxidative burst necessary to the intracellular inactivation of microorganisms and predisposes to an increased risk of infections by various microorganisms, including fungi like Aspergillus spp. and other less frequently encountered or emerging fungal species. Here we review the genetic basis, pathogenesis and clinical presentation associated with fungal infections in chronic granulomatous disease as well as the current prophylaxis and newly available therapies.
© 2012 médecine/sciences – Inserm / SRMS.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / therapeutic use*
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / etiology
-
Aspergillosis / immunology
-
Aspergillosis / therapy
-
Disease Susceptibility
-
Genetic Therapy
-
Granulomatous Disease, Chronic / complications*
-
Granulomatous Disease, Chronic / enzymology
-
Granulomatous Disease, Chronic / epidemiology
-
Granulomatous Disease, Chronic / immunology
-
Granulomatous Disease, Chronic / surgery
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunocompromised Host
-
Incidence
-
Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism
-
Lymphocyte Subsets / immunology
-
Mice
-
Mycoses / epidemiology
-
Mycoses / etiology*
-
Mycoses / immunology
-
Mycoses / prevention & control
-
Mycoses / therapy
-
NADPH Oxidases / deficiency
-
NADPH Oxidases / genetics
-
NADPH Oxidases / physiology
-
Neutrophils / enzymology
-
Neutrophils / immunology
-
Protein Subunits
-
Respiratory Burst
-
Tryptophan / metabolism
Substances
-
Anti-Inflammatory Agents
-
Antifungal Agents
-
Indoleamine-Pyrrole 2,3,-Dioxygenase
-
Protein Subunits
-
Tryptophan
-
NADPH Oxidases